Mandate

Vinge advises IRLAB Therapeutics in connection with share issues

December 13, 2019 Capital Markets and Public M&A

Vinge advises IRLAB Therapeutics in connection with a directed share issue of SEK 70 million and a rights issue of approximately SEK 145 million.

The directed share issue was subscribed for by a number of institutional and qualified investors on the basis of an accelerated book building process. The rights issue is expected to be completed during the first quarter of 2020.

IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier Growth Market, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Stephanie Stiernstedt, Stojan Arnerstål, Anna Thoms and Maria Schultzberg.

Related

Vinge advises MAAG Gear with its MEUR 18.5 refinancing

Vinge has advised MAAG Gear in connection with entering into a EUR 18 500 000 facility agreement with Danske Bank A/S for the purpose of, among other things, refinancing its previous credit. MAAG Gear is a leading manufacturer of industrial gear solutions for cement and mining applications with a comprehensive product portfolio and global aftermarket services offering.
August 21, 2025

Vinge has advised Direktronik in conjunction with the acquisition of Qvintus

Direktronik, a subsidiary of Lagercrantz Group, has acquired all shares in Qvintus.
August 19, 2025

Vinge advises Sobro in conjunction with investment in vChain

vTrade, together with its subsidiary vChain, has decided to broaden its shareholder base with Sobro as a new owner and majority shareholder. Founder Carl-Henrik Lundh will continue as CEO and significant shareholder.
August 18, 2025